Moderna Non Current Liabilities Other from 2010 to 2024
| MRNA Stock | USD 38.25 1.31 3.55% |
Non Current Liabilities Other | First Reported 2019-03-31 | Previous Quarter 262 M | Current Value 266 M | Quarterly Volatility 299 M |
Check Moderna financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moderna's main balance sheet or income statement drivers, such as Interest Expense of 39.9 M, Selling General Administrative of 1.4 B or Total Revenue of 4.9 B, as well as many indicators such as Price To Sales Ratio of 5.27, Dividend Yield of 1.0E-4 or PTB Ratio of 2.61. Moderna financial statements analysis is a perfect complement when working with Moderna Valuation or Volatility modules.
Moderna | Non Current Liabilities Other |
Latest Moderna's Non Current Liabilities Other Growth Pattern
Below is the plot of the Non Current Liabilities Other of Moderna over the last few years. It is Moderna's Non Current Liabilities Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moderna's overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Other | 10 Years Trend |
|
Non Current Liabilities Other |
| Timeline |
Moderna Non Current Liabilities Other Regression Statistics
| Arithmetic Mean | 165,500,206 | |
| Geometric Mean | 6,103,551 | |
| Coefficient Of Variation | 220.28 | |
| Mean Deviation | 223,446,435 | |
| Median | 1,104,000 | |
| Standard Deviation | 364,567,944 | |
| Sample Variance | 132909.8T | |
| Range | 1.4B | |
| R-Value | 0.48 | |
| Mean Square Error | 109775.1T | |
| R-Squared | 0.23 | |
| Significance | 0.07 | |
| Slope | 39,354,634 | |
| Total Sum of Squares | 1860737T |
Moderna Non Current Liabilities Other History
About Moderna Financial Statements
Moderna stakeholders use historical fundamental indicators, such as Moderna's Non Current Liabilities Other, to determine how well the company is positioned to perform in the future. Although Moderna investors may analyze each financial statement separately, they are all interrelated. For example, changes in Moderna's assets and liabilities are reflected in the revenues and expenses on Moderna's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Moderna. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Other | 256 M | 299.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:Check out the analysis of Moderna Correlation against competitors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.85) | Earnings Share (5.81) | Revenue Per Share 13.275 | Quarterly Revenue Growth 0.017 | Return On Assets (0.1) |
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.